{"doi":"10.1136/rmdopen-2022-002935","title":"Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism","abstract":"Background The frequency of proteinase 3 gene (PRTN3) polymorphisms in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is not fully characterised. We hypothesise that the presence of a PRTN3 gene polymorphism (single nucleotide polymorphism (SNP) rs351111) is relevant for clinical outcomes. Methods DNA variant calling for SNP rs351111 (chr.19:844020, c.355G>A) in PRTN3 gene assessed the allelic frequency in patients with PR3-AAV included in the Rituximab in ANCA-Associated Vasculitis trial. This was followed by RNA-seq variant calling to characterise the mRNA expression. We compared clinical outcomes between patients homozygous for PRTN3-Ile 119 or PRTN3-Val 119 . Results Whole blood samples for DNA calling were available in 188 patients. 75 patients with PR3-AAV had the allelic variant: 62 heterozygous PRTN3-Val 119 Ile and 13 homozygous for PRTN3-Ile 119 . RNA-seq was available for 89 patients and mRNA corresponding to the allelic variant was found in 32 patients with PR3-AAV: 25 heterozygous PRTN3-Val 119 Ile and 7 homozygous for PRTN3-Ile 119 . The agreement between the DNA calling results and mRNA expression of the 86 patients analysed by both methods was 100%. We compared the clinical outcomes of 64 patients with PR3-AAV: 51 homozygous for PRTN3-Val 119 and 13 homozygous for PRTN3-Ile 119 . The frequency of severe flares at 18 months in homozygous PRTN3-Ile 119 was significantly higher when compared with homozygous PRTN3-Val 119 (46.2% vs 19.6%, p=0.048). Multivariate analysis identified homozygous PR3-Ile 119 as main predictor of severe relapse (HR 4.67, 95% CI 1.16 to 18.86, p=0.030). Conclusion In patients with PR3-AAV, homozygosity for PRTN3-Val 119 Ile polymorphism appears associated with higher frequency of severe relapse. Further studies are necessary to better understand the association of this observation with the risk of severe relapse.","journal":"RMD Open","year":2023,"id":365367,"datarank":0.29188652235829704,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"self_citation_contribution":0.29188652235829704,"citation_network_contribution":0.0,"self_endowment_contribution":0.29188652235829704,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9645,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":4101,"name":"Zuoming Deng","orcid":null,"position":1,"is_corresponding":false},{"id":218255,"name":"Stephen R. Brooks","orcid":"0000-0001-5592-5332","position":2,"is_corresponding":false},{"id":1121262,"name":"Wei Tew","orcid":null,"position":3,"is_corresponding":false},{"id":242666,"name":"Fernando C. Fervenza","orcid":"0000-0002-9952-209X","position":4,"is_corresponding":false},{"id":25204,"name":"Cees G. M. Kallenberg","orcid":null,"position":5,"is_corresponding":false},{"id":251775,"name":"Carol A. Langford","orcid":"0000-0001-9498-321X","position":6,"is_corresponding":false},{"id":5969,"name":"Peter A. Merkel","orcid":"0000-0001-9284-7345","position":7,"is_corresponding":false},{"id":61593,"name":"Paul A. Monach","orcid":"0000-0003-4937-0515","position":8,"is_corresponding":false},{"id":328460,"name":"Philip Seo","orcid":"0000-0003-3435-6737","position":9,"is_corresponding":false},{"id":251783,"name":"Robert Spiera","orcid":"0000-0003-2911-6800","position":10,"is_corresponding":false},{"id":280488,"name":"E. William St. Clair","orcid":"0000-0003-1181-0650","position":11,"is_corresponding":false},{"id":25215,"name":"John H. Stone","orcid":"0000-0001-6588-9435","position":12,"is_corresponding":false},{"id":323636,"name":"Marco Prunotto","orcid":"0000-0002-0203-0129","position":13,"is_corresponding":false},{"id":5958,"name":"Peter C. Grayson","orcid":"0000-0002-8269-9438","position":14,"is_corresponding":false},{"id":25214,"name":"Ulrich Specks","orcid":"0000-0002-6559-1206","position":15,"is_corresponding":false},{"id":898198,"name":"Marta Casal Moura","orcid":"0000-0001-7439-6501","position":0,"is_corresponding":true}],"reference_count":19,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T01:14:46.760245Z","pmid":"36990659","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}